AGIOS PHARMACEUTICALS, INC. (AGIO) Free cash flow
- Free cash flow · 12 months (USD): Value $-365.25M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -371.43%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-365.25M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-360.60M − $4.66M ≈ $-365.25M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -371.43% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-365.25M ÷ $98.34M × 100 ≈ -371.43% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-360.60M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.88× | Operating cash flow / net income. Period ending 2026-06-30. $-360.60M ÷ $-411.50M ≈ 0.88× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -360.60M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 4.66M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -365.25M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 98.34M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -411.50M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-365.25M | (m) | $-360.60M | $4.66M | (m) | $98.34M | (m) | $-411.50M | (m) | (m) | -371.43% | 0.88× |
| 2026-03-31 | $-384.73M | (m) | $-380.41M | $4.32M | (m) | $66.05M | (m) | $-422.82M | (m) | (m) | -582.50% | 0.90× |
| 2025-12-31 | $-377.29M | (m) | $-372.98M | $4.32M | (m) | $54.03M | (m) | $-412.78M | (m) | (m) | -698.33% | 0.90× |
| 2025-09-30 | $-414.09M | (m) | $-409.93M | $4.16M | (m) | $44.79M | (m) | $-401.26M | (m) | (m) | -924.50% | 1.02× |
| 2025-06-30 | $-409.02M | (m) | $-406.00M | $3.03M | (m) | $40.88M | (m) | $650.08M | (m) | (m) | -1000.67% | -0.62× |
| 2025-03-31 | $-403.77M | (m) | $-401.46M | $2.31M | (m) | $37.03M | (m) | $665.99M | (m) | (m) | -1090.25% | -0.60× |
| 2024-12-31 | $-391.53M | (m) | $-389.84M | $1.69M | (m) | $36.50M | (m) | $673.73M | (m) | (m) | -1072.73% | -0.58× |
| 2024-09-30 | $-330.11M | (m) | $-329.16M | $952.00K | (m) | $32.87M | (m) | $674.31M | (m) | (m) | -1004.27% | -0.49× |
| 2024-06-30 | $-307.49M | (m) | $-306.59M | $902.00K | (m) | $31.31M | (m) | $-364.93M | (m) | (m) | -982.20% | 0.84× |
| 2024-03-31 | $-301.49M | (m) | $-300.75M | $741.00K | (m) | $29.40M | (m) | $-352.62M | (m) | (m) | -1025.36% | 0.85× |
| 2023-12-31 | $-297.06M | (m) | $-296.06M | $999.00K | (m) | $26.82M | (m) | $-352.09M | (m) | (m) | -1107.49% | 0.84× |
| 2023-09-30 | $-290.62M | (m) | $-289.74M | $878.00K | (m) | $24.03M | (m) | $-219.62M | (m) | (m) | -1209.38% | 1.32× |
| 2023-06-30 | $-299.99M | (m) | $-299.44M | $547.00K | (m) | $20.15M | (m) | $-210.04M | (m) | (m) | -1489.02% | 1.43× |
| 2023-03-31 | $-309.40M | (m) | $-306.93M | $2.48M | (m) | $19.02M | (m) | $-218.04M | (m) | (m) | -1626.98% | 1.41× |
| 2022-12-31 | $-314.36M | (m) | $-309.48M | $4.88M | (m) | $14.24M | (m) | $-231.80M | (m) | (m) | -2207.58% | 1.34× |
| 2022-09-30 | $-336.68M | (m) | $-327.41M | $9.27M | (m) | (m) | (m) | $-362.95M | (m) | (m) | (m) | 0.90× |
| 2022-06-30 | $-350.45M | (m) | $-341.24M | $9.21M | (m) | (m) | (m) | $-369.97M | (m) | (m) | (m) | 0.92× |
| 2022-03-31 | $-391.84M | (m) | $-384.31M | $7.53M | (m) | (m) | (m) | $-364.38M | (m) | (m) | (m) | 1.05× |
| 2021-12-31 | $-413.06M | (m) | $-407.32M | $5.74M | (m) | (m) | (m) | $1.60B | (m) | (m) | (m) | -0.25× |
| 2021-09-30 | $-375.23M | (m) | $-372.62M | $2.60M | (m) | (m) | (m) | $1.60B | (m) | (m) | (m) | -0.23× |
| 2021-06-30 | $-363.48M | (m) | $-355.65M | $7.83M | (m) | (m) | (m) | $1.59B | (m) | (m) | (m) | -0.22× |
| 2021-03-31 | $-317.88M | (m) | $-306.15M | $11.72M | (m) | (m) | (m) | $1.59B | (m) | (m) | (m) | -0.19× |
| 2020-12-31 | $-305.67M | (m) | $-290.76M | $14.91M | (m) | $203.20M | (m) | $-327.37M | (m) | (m) | -150.43% | 0.89× |
| 2020-09-30 | $-355.69M | (m) | $-334.97M | $20.72M | (m) | $194.59M | (m) | $-332.06M | (m) | (m) | -182.79% | 1.01× |
| 2020-06-30 | $-369.90M | (m) | $-352.36M | $17.55M | (m) | $185.91M | (m) | $-339.26M | (m) | (m) | -198.97% | 1.04× |
| 2020-03-31 | $-387.30M | (m) | $-372.71M | $14.59M | (m) | $174.78M | (m) | $-358.65M | (m) | (m) | -221.59% | 1.04× |
| 2019-12-31 | $-382.79M | (m) | $-370.62M | $12.17M | (m) | $117.91M | (m) | $-411.47M | (m) | (m) | -324.64% | 0.90× |
| 2019-09-30 | $-357.60M | (m) | $-351.20M | $6.40M | (m) | $112.48M | (m) | $-400.92M | (m) | (m) | -317.91% | 0.88× |
| 2019-06-30 | $-336.95M | (m) | $-329.45M | $7.50M | (m) | $101.66M | (m) | $-389.41M | (m) | (m) | -331.45% | 0.85× |
| 2019-03-31 | $-316.28M | (m) | $-308.69M | $7.59M | (m) | $115.85M | (m) | $-348.28M | (m) | (m) | -273.01% | 0.89× |
| 2018-12-31 | $-311.41M | (m) | $-304.42M | $6.99M | (m) | $94.39M | (m) | $-346.03M | (m) | (m) | -329.93% | 0.88× |
| 2018-09-30 | $-311.90M | (m) | $-304.69M | $7.21M | (m) | $74.17M | (m) | $-342.52M | (m) | (m) | -420.50% | 0.89× |
| 2018-06-30 | $-324.66M | (m) | $-318.56M | $6.09M | (m) | $70.33M | (m) | $-324.99M | (m) | (m) | -461.60% | 0.98× |
| 2018-03-31 | $-315.92M | (m) | $-310.16M | $5.77M | (m) | $41.27M | (m) | $-339.33M | (m) | (m) | -765.60% | 0.91× |
| 2017-12-31 | $-289.86M | (m) | $-285.23M | $4.63M | (m) | $43.01M | (m) | $-314.67M | (m) | (m) | -673.92% | 0.91× |
| 2017-09-30 | $-266.57M | (m) | $-262.00M | $4.57M | (m) | (m) | (m) | $-282.87M | (m) | (m) | (m) | 0.93× |
| 2017-06-30 | $-239.29M | (m) | $-233.32M | $5.98M | (m) | (m) | (m) | $-268.57M | (m) | (m) | (m) | 0.87× |
| 2017-03-31 | $-24.18M | (m) | $-16.50M | $7.67M | (m) | (m) | (m) | $-241.44M | (m) | (m) | (m) | 0.07× |
| 2016-12-31 | $28.65M | (m) | $38.56M | $9.91M | (m) | $69.89M | (m) | $-198.47M | (m) | (m) | 40.99% | -0.19× |
| 2016-09-30 | $48.38M | (m) | $59.26M | $10.88M | (m) | (m) | (m) | $-182.61M | (m) | (m) | (m) | -0.32× |
| 2016-06-30 | $72.72M | (m) | $83.47M | $10.75M | (m) | (m) | (m) | $-160.03M | (m) | (m) | (m) | -0.52× |
| 2016-03-31 | $-89.27M | (m) | $-70.37M | $18.90M | (m) | (m) | (m) | $-135.97M | (m) | (m) | (m) | 0.52× |
| 2015-12-31 | $-97.11M | (m) | $-76.95M | $20.16M | (m) | $59.12M | (m) | $-117.73M | (m) | (m) | -164.27% | 0.65× |
| 2015-09-30 | $-73.66M | (m) | $-54.20M | $19.47M | (m) | (m) | (m) | $-103.77M | (m) | (m) | (m) | 0.52× |
| 2015-06-30 | $-69.64M | (m) | $-52.85M | $16.80M | (m) | (m) | (m) | $-59.81M | (m) | (m) | (m) | 0.88× |
| 2015-03-31 | $-63.90M | (m) | $-57.90M | $6.00M | (m) | (m) | (m) | $-46.21M | (m) | (m) | (m) | 1.25× |
| 2014-12-31 | $-61.57M | (m) | $-59.35M | $2.22M | (m) | $65.36M | (m) | $-53.50M | (m) | (m) | -94.20% | 1.11× |
| 2014-09-30 | $-66.14M | (m) | $-65.19M | $946.00K | (m) | (m) | (m) | $-39.22M | (m) | (m) | (m) | 1.66× |
| 2014-06-30 | $-57.13M | (m) | $-56.71M | $417.00K | (m) | $29.85M | (m) | $-54.10M | (m) | (m) | -191.39% | 1.05× |
| 2014-03-31 | $-72.49M | (m) | $-71.46M | $1.03M | (m) | $27.65M | (m) | $-44.43M | (m) | (m) | -262.19% | 1.61× |
| 2013-12-31 | $-57.69M | (m) | $-56.40M | $1.29M | (m) | $25.55M | (m) | $-39.41M | (m) | (m) | -225.83% | 1.43× |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | $25.14M | (m) | $-22.70M | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-51.02M | (m) | $-49.55M | $1.48M | (m) | $25.11M | (m) | $-20.10M | (m) | (m) | -203.23% | 2.46× |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-17.13M | (m) | $-15.22M | $1.91M | (m) | $21.84M | (m) | $-23.71M | (m) | (m) | -78.42% | 0.64× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |